Who
Mani Mohindru
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Cardiff Oncology; Director, CytomX Therapeutics; CFO & Chief Strategy Officer, Tvardi Therapeutics; Chief Strategy Officer, Curis.
In numbers
- Trades disclosed
- 46
- Buys
- 2
- Sells
- 7
- Bought
- $160K
- Sold
- $2.1M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 19 Jan 2016
- Last trade
- 14 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $50K34,364 at $1.46 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code P | —34,364 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code P | —34,364 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $50K34,364 at $1.46 | filing |
| 18 Jun 2026filed 22 Jun 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $30K24,703 at $1.21 | filing |
| 18 Jun 2026filed 22 Jun 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $30K24,703 at $1.21 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
News
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaCRDF · manilatimes.net · 21 Oct 2026Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)CRDF · themarketsdaily.com · 21 Oct 2026Contrasting Nektar Therapeutics (NASDAQ:NKTR) and Cardiff Oncology (NASDAQ:CRDF)CRDF · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Mani Mohindru; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.